Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32469182

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2020 Jun 18
First author
Shitara K

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2020 Sep;17(9):521. doi: 10.1038/s41571-020-0406-y.
    note
    Source null
    related pmid
    32533051
    relationship
    Comment in
  2. citation
    Cancer Cell. 2020 Sep 14;38(3):317-319. doi: 10.1016/j.ccell.2020.07.012.
    note
    Source null
    related pmid
    32857948
    relationship
    Comment in

Authors and identifiers

  1. name
    Shitara K
    type
    Author
  2. name
    Bang YJ
    type
    Author
  3. name
    Iwasa S
    type
    Author
  4. name
    Sugimoto N
    type
    Author
  5. name
    Ryu MH
    type
    Author
  6. name
    Sakai D
    type
    Author
  7. name
    Chung HC
    type
    Author
  8. name
    Kawakami H
    type
    Author
  9. name
    Yabusaki H
    type
    Author
  10. name
    Lee J
    type
    Author
  11. name
    Saito K
    type
    Author
  12. name
    Kawaguchi Y
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Shitara K
    type
    Author
  2. name
    Bang YJ
    type
    Author
  3. name
    Iwasa S
    type
    Author
  4. name
    Sugimoto N
    type
    Author
  5. name
    Ryu MH
    type
    Author
  6. name
    Sakai D
    type
    Author
  7. name
    Chung HC
    type
    Author
  8. name
    Kawakami H
    type
    Author
  9. name
    Yabusaki H
    type
    Author
  10. name
    Lee J
    type
    Author
  11. name
    Saito K
    type
    Author
  12. name
    Kawaguchi Y
    type
    Author
bibliography ids
  1. nci-bib-c980aca826760a7081835995
book metadata
content sha256
6f0e644799f8dbff199e2a5e01edfe8022548045d28deca8ecae0b828084db04
document type
citation
dois
  1. 10.1056/NEJMoa2004413
electronic publication date
display
2020 May 29
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32469182
immutable id
pubmed:32469182@6f0e644799f8dbff199e2a5e01edfe8022548045d28deca8ecae0b828084db04
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
25
name
The New England journal of medicine
nlm unique id
0255562
pages
2419-2430
volume
382
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2020 Sep;17(9):521. doi: 10.1038/s41571-020-0406-y.
    note
    Source null
    related pmid
    32533051
    relationship
    Comment in
  2. citation
    Cancer Cell. 2020 Sep 14;38(3):317-319. doi: 10.1016/j.ccell.2020.07.012.
    note
    Source null
    related pmid
    32857948
    relationship
    Comment in
outcomes validated
false
pmid
32469182
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
d55f0aafac0260dcbc03655e5672daed7cda60839c9de6c0b64a0039da526922
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 Jun 18
precision
day
year
2020
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32469182/
title
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

Preserved source evidence · Not medical advice